Page 35 - 80_02

Los
cocristales
farmacéuticos…

21. Leyssens,
T.;
Springuel,
G.;
Montis,
R.,
Candoni,
N.;
Veesler,
S.
Importance
of
Solvent

Selection
for
Stoichiometrically
Diverse
Cocrystal
Systems:
Caffeine/Maleic
Acid
1:1
and

2:1
Cocrystals.
Cryst.
Growth
Des.
12,
1520-­-1530
(2012).

22. Aitipamula,
S.;
Chowa,
P.
S.;
Tan,
R.
B.
H.
(2009).
Theophylline–gentisic
acid

(1/1).ActaCrystallogr.,
Sect.
E:
Struct.
Rep.
OnlineE65,
o2126-­-o2127.

23. Karki,
S.;
Fabian,
L.;
Friscic,
T.;
Jones,
W.
Powder
X-­-ray
Diffraction
as
an
Emerging
Method

to
Structurally
Characterize
Organic
Solids.
Org.
Lett.9,
3133-­-3136
(2007).

24. Chieng,
N.;
Hubert,
M.;
Saville,
D.;
Rades,
T.;
Aaltonen,
J.
Formation
Kinetics
and
Stability
of

Carbamazepine-­-NicotinamideCocrystals
Prepared
by
Mechanical
Activation.
Cryst.
Growth

Des.9,
2377-­-2386
(2009).

25. Bucar,
D.K.;
Henry,
R.
F.;
Lou,
X.;
Richard
W.
D;
MacGillivray,
L.
R.;
Zhang,
G.
G.
Z.
Cocrystals

of
Caffeine
and
Hydroxybenzoic
Acids
Composed
of
Multiple

SupramolecularHeterosynthons:
Screening
via
Solution-­-Mediated
Phase
Transformation

and
Structural
Characterization.
Cryst.
Growth
Des.9,
1932-­-1943
(2009).

26. Lu,
E.;
Rodríguez-­-Hornedo,
N.;
Suryanarayanan,
R.
A
rapid
thermal
method
for
cocrystal

screening.CrystEngComm.10,
665-­-668
(2008).

27. Sun,
C.
C.;
Hou,
H.
Improving
Mechanical
Properties
of
Caffeine
and
Methyl
Gallate
Crystals

by
Cocrystallization.
Crystal
Growth
Des.8,
1575-­-1579
(2008).

28. International
Conference
on
Harmonization
(ICH).
ICH
Harmonized
Tripartite
Guideline:

Stability
Testing
of
New
Drugs
Substances
and
Products
Q1A(R2)
(2003).

http://www.ich.org/products/guidelines/quality/quality-­-single/article/stability-­-testing-­-
of-­-new-­-drug-­-substances-­-and-­-products.html

29. Trask,
A.
V.;
Motherwell,
W.
D.
S.;
Jones,
W.
Pharmaceutical
Cocrystallization:
Engineering

a
Remedy
for
Caffeine
Hydration.
Cryst.
Growth
Des.5,
1013-­-1021
(2005).

30. Tomaszewska,
I.;Karki,
S.;
Shur,
J.;
Price,
R.;
Fotaki,
N.
Pharmaceutical
characterisation
and

evaluation
of
cocrystals:
Importance
of
in
vitro
dissolution
conditions
and
type
of

coformer.
Int.
J.
Pharm.453,
380-­-388
(2013).

31. Mohanachandran,
P.
S.;
Sindhumol,
P.
G.;
Kiran,
T.
S.
Enhancement
of
solubility
and

dissolution
rate:
An
overview.
Pharm.
Globale,
4,
1-­-10
(2010).

32. Thakuria,
R.;
Delori,
A.;
Jones,
W.;
Lipert,
M.
P.;
Roy,
L.;
Rodríguez-­-Hornedo,
N.

Pharmaceutical
cocrystals
and
poorly
soluble
drugs.
Int.
J.
Pharm.453,
101-­-125
(2013).

33. Elder,
D.
P.;
Holm,
R.;
Diego,
H.
L.
Use
of
pharmaceutical
salts
and
cocrystals
to
address
the

issue
of
poor
solubility.
Int.
J.
Pharm.,
453,
88-­-100
(2013).

34. Smith,
A.
J.;
Kavuru,
P.;
Wojtas,
L.;
Zaworotko,
M.
J.;
Shytle,
R.
D.
Cocrystals
of
Quercetin

with
Improved
Solubility
and
Oral
Bioavailability.
Mol.
Pharm.8,
1867-­-1876
(2011).

35. Hickey,
M.
B.;
Peterson,
M.
L.;
Scoppettuolo,
L.
A.;Morrisette,
S.
L.;
Vetter,
A.;
Guzmán,
H.,

Remenar,
J.
F.;
Zhang,
Z.;
Tawa,
M.
D.;
Haley,
S.;
Zaworotko,
M.
J.;
Almarsson,
O.

Performance
comparison
of
a
co-­-crystal
of
carbamazepine
with
marketed
product.
Eur.
J.

of
Pharm.
Biopharm.,67,
112-­-119
(2007).

36. Zhang,
T.-­-T.;
Wang,
H.-­-T.;
Jia,
J.-­-T.;
Cui,
X.-­-Q.;
Li,
Q.;Zhu,
G.-­-S.
Syntheses
and

pharmacokinetics
properties
of
an
iloperidone
pharmaceutical
cocrystal.
Inorg.
Chem.

Commun.
39,
144-­-146
(2014).

37. Trask,
A.
V.
An
Overview
of
Pharmaceutical
Cocrystals
as
Intellectual
Property.Mol.

Pharm.4,
301-­-309
(2007).

38. Center
for
Drug
Evaluation
and
Research.
Regulatory
Classification
of
Pharmaceutical
Co-­-
Crystals.
United
States
Food
and
Drug
Administration
(2013).

http://www.fda.gov/downloads/Drugs/Guidances/UCM281764.pdf

39. Brittain,
H.
G.
Cocrystal
Systems
of
Pharmaceutical
Interest:
2011.
Cryst.
Growth
Des.12,

5823-­-5832
(2011).

40. Brittain,
H.
G.
Cocrystal
Systems
of
Pharmaceutical
Interest:
2010.
Cryst.
Growth
Des.12,

1046-­-1054
(2012).

273